News
CD38 regulates HSCs activation and Aging
The Chen lab at UC Berkeley discovered that CD38 functions as a NAD-dependent metabolic checkpoint, which regulates Hematopoietic Stem Cell (HSC) activation and aging. HSCs, being a rare cell type of particular interest in leukemia therapy, play a crucial role in hematopoietic homeostasis. The current detailed study of HSC metabolism provides new insights into the […]
1st Annual Hi-D FACS Conference
I am thrilled to announce 1st Annual Hi-D FACS Conference. Cancer Research Laboratory FACS Core Facility is co-hosting this event in collaboration with BD Biosciences. A special thanks to Dr. Russell Vance for supporting this event. Looking forward to see you there. Reserve your spot here! https://bit.ly/bd-thnkspectral-032024
World 1st ever, accredited academic, Flow Cytometry Course
“drop-by-drop, cell-by-cell, excites, emits nobel tale” Fall 2023; Congratulations to my dear students who have successfully graduated from the 1st ever accredited academic FACS (Fluorescence Activated Cell Sorting) course (2 units, 14 weeks/semester)
Come to Advanced Imaging Methods January 23 – 25, 2024
We hope you can join us at our next AIM Workshop on campus this year! http://aim2024.eventbrite.com
AIM 2023 Back In Person!
We are so thrilled to be able to be back in person for our 20th Anniversary! That’s right, the 20th Advanced Imaging Methods Workshop will be held in Berkeley, California, January 24 – 26, 2023, at the beautiful new conference center at the Residence Inn by Marriott. https://aim2023.eventbrite.com/ We hope you can join us!
Jim Allison Commencement Address at UC Berkeley
James P. Allison, University of Texas, MD Anderson Cancer Center. Commencement Address. University of California at Berkeley. Department of Molecular and Cell Biology PhD Program. May 19, 2017 [Prepared remarks, lightly edited] MCB graduates, Class of 2017 – Congratulations! I have the honor today to offer my congratulations on finishing, or should I say surviving, […]
How Cancer Biologists and Infectious Disease Immunologists Can Learn From Each Other
The yin-yang of cancer and infectious disease
On the importance of fundamental research
In a podcast, hosted by the Journal of Immunology, Professor David H. Raulet discusses the importance of fundamental research. The podcast is available here, and refers to a Pillars of Immunology article published previously by David Raulet, highlighting a pair of classic 1971 articles by Cudkowicz and Bennett. The article and podcast provide yet another example of how […]
June is Cancer Immunotherapy Month
With our close partners at the Cancer Research Institute, the CRL is pleased to highlight June as Cancer Immunotherapy Month. The past year has seen immunotherapy ever more in the news. For example, in March of this year, Jimmy Carter announced that immunotherapy had successfully treated his melanoma. And in January, spurred on in large part […]
From food poisoning to cancer immunotherapy
How has research at UC Berkeley on a soil bacterium called Listeria monocytogenes led to new approaches to cancer treatment? The Cancer Research Lab is founded on the belief that fundamental research can lead to novel and entirely unexpected approaches to cancer therapy. This belief is exemplified by the remarkable story of how research in Professor […]
Immunotherapeutics and Vaccine Research Initiative (IVRI)
The CRL and CEND (The Center for Emerging and Neglected Diseases) are joining forces to help launch a new campus initiative. The new initiative is called the Immunotherapeutics and Vaccine Research Initiative or IVRI, and is being launched officially on March 24-25, 2016 to coincide with a Symposium on Immunotherapy on the UC Berkeley campus. […]
CEND/IVRI Symposium on Immunotherapy at UC Berkeley
The CRL is joining forces with two campus organizations to sponsor an exciting new Symposium at UC Berkeley on Immunotherapy. The CRL will join the Henry Wheeler Center for Emerging & Neglected Diseases (CEND) and the new Immunotherapeutics and Vaccine Research Initiative (IVRI) to sponsor a Symposium that aims to strengthen connections between scientists working […]
Lasker Award for CRL Immunotherapy Research
Congratulations to former CRL Director James P. Allison for winning the 2015 Lasker-DeBakey Clinical Medical Research Award. The Lasker Committee recognized Dr. Allison’s groundbreaking work on immunotherapy of cancer, specifically citing “the discovery and development of a monoclonal antibody therapy that unleashes the immune system to combat cancer.” The work recognized by the Lasker Award […]
June is Cancer Immunotherapy Month
The UC Berkeley Cancer Research Lab is joining the Cancer Research Institute to promote June as Cancer Immunotherapy Month. The Cancer Research Laboratory (CRL) at UC Berkeley has played a key role in the development of novel cancer immunotherapies. In particular the idea of checkpoint blockade was developed by Prof James Allison when he was Director of […]
Berkeley leading the way on new approaches to cancer immunotherapy
A newly announced biotech deal shows how basic research at UC Berkeley is leading to new therapeutic approaches for cancer. Novartis has just announced a major $750M partnership with Berkeley-based Aduro BioTech to develop a new class of molecules, called CDNs, as a potential immunotherapy for cancer. These molecules were first discovered in bacteria, but the […]
CRL researchers identify a new approach to cancer immunotherapy
David Raulet’s lab, affiliated with the UC Berkeley Cancer Research Laboratory, has published a new paper in Science. The new research, published online on March 5, suggests a new approach to cancer immunotherapy, and pertains to a special class of immune cells called Natural Killer cells. These cells normally patrol the body, seeking out abnormal cells […]
CRL collaborators on new $4.3M grant awarded to study the brain
The Cancer Research Lab is proud announce we are collaborators on a new $4.3M grant from the National Institutes of Health. The grant was awarded to CRL affiliated faculty member Prof John Ngai and a team of associated researchers. The new research will help identify and characterize neuronal cell types in the brain. The CRL will participate […]
Scientist’s Drive Puts the Brakes on Cancer
The Association of University Technology Managers (AUTM) has posted an article describing Jim Allison’s work in the CRL. The article describes how Jim’s work in the Cancer Research Lab at UC Berkeley led to a novel FDA-approved therapy for melanoma: As a kid, James Allison loved to figure out how things worked. “I wanted to […]
Single Cell Western Blotting
The Herr and Schaffer labs at UC Berkeley describe the development of a new technology called Single Cell Western Blotting. This new technology, which allows for unprecedented analysis of protein expression at the single cell level, was developed in conjunction with Dr. Kartoosh Heydari at the CRL Flow Cytometry Facility. For more information see http://www.ncbi.nlm.nih.gov/pubmed/24880876.
Berkeley Professors newly elected to the National Academy of Sciences
The CRL would like to congratulate the five Berkeley faculty that have been newly elected to the National Academy of Sciences, one of the highest national honors that can be bestowed to a scientist. We would particularly like to congratulate our own Richard Harland
Jim Allison confronts cancer, critics with immunotherapy
The San Francisco Chronicle published a profile on Jim Allison, who performed much of his breakthrough cancer research in the Cancer Research Laboratory at UC Berkeley.
CRL Researchers show how MicroRNAs protect against tumors
Two new papers published by Cancer Research Laboratory scientists have shown how unique cellular regulators called “microRNAs” can protect against tumors. The first paper, published by the laboratory of Prof. Lin He in the journal Genes & Development, shows how a particular microRNA called miR-34 can induce the important tumor suppressor gene p53. This effect […]
Breakthrough Of The Year
The editors of Science magazine have chosen Cancer Immunotherapy as their Breakthrough of the Year for 2013. The magazine cover image features work done in the Cancer Research Laboratory at Berkeley in the 1990s by Jim Allison and colleagues. See the December 20th issue of Science for more details or read about the groundbreaking cancer […]
Yervoy (Ipilimumab)
In the late 1990s, while serving as the Director of the UC Berkeley Cancer Research Laboratory, Jim became intrigued by a special biological molecule called CTLA-4. This molecule was displayed on the surface of particular cells in the immune system called T cells. Jim and his colleagues — most notably, graduate student Max Krummel, and […]
